PURPOSE: To evaluate topical interferon alfa-2b (IFN-alpha2b) for the treatment of recalcitrant ocular surface squamous neoplasia (OSSN). DESIGN: Prospective, noncomparative, interventional consecutive case series. METHODS: Ten patients with recalcitrant OSSN were treated with topical IFN-alpha2b (1 million IU/ml) four times a day until clinical resolution of the lesion or until the lesion appeared nonresponsive-that is, treatment failure. Progress was assessed by clinical examination and photographic records, with a minimum follow-up of six months. RESULTS: Eight of 10 patients achieved clinical resolution from topical IFN-alpha2b treatment. One patient developed invasive squamous cell carcinoma and underwent exenteration. The other patient required further mitomycin C therapy to achieve clinical resolution. The mean duration to clinical resolution for the eight patients treated with IFN-alpha2b was 21.9 weeks (range six to 59 weeks). There have been no recurrences for any of the nine patients during follow-up (mean 55.0 weeks; range 26 to 84 weeks). CONCLUSIONS: Topical IFN-alpha2b is an important treatment modality for recalcitrant OSSN; it avoids the risks of further limbal stem cell destruction from other agents and surgical excision. If invasive disease is diagnosed at any stage, topical therapy is contraindicated, necessitating surgical excision.
PURPOSE: To evaluate topical interferon alfa-2b (IFN-alpha2b) for the treatment of recalcitrant ocular surface squamous neoplasia (OSSN). DESIGN: Prospective, noncomparative, interventional consecutive case series. METHODS: Ten patients with recalcitrant OSSN were treated with topical IFN-alpha2b (1 million IU/ml) four times a day until clinical resolution of the lesion or until the lesion appeared nonresponsive-that is, treatment failure. Progress was assessed by clinical examination and photographic records, with a minimum follow-up of six months. RESULTS: Eight of 10 patients achieved clinical resolution from topical IFN-alpha2b treatment. One patient developed invasive squamous cell carcinoma and underwent exenteration. The other patient required further mitomycin C therapy to achieve clinical resolution. The mean duration to clinical resolution for the eight patients treated with IFN-alpha2b was 21.9 weeks (range six to 59 weeks). There have been no recurrences for any of the nine patients during follow-up (mean 55.0 weeks; range 26 to 84 weeks). CONCLUSIONS: Topical IFN-alpha2b is an important treatment modality for recalcitrant OSSN; it avoids the risks of further limbal stem cell destruction from other agents and surgical excision. If invasive disease is diagnosed at any stage, topical therapy is contraindicated, necessitating surgical excision.
Authors: Christina S Moon; Afshan A Nanji; Anat Galor; Kathryn E McCollister; Carol L Karp Journal: Ophthalmology Date: 2015-12-11 Impact factor: 12.079
Authors: Afshan A Nanji; Christina S Moon; Anat Galor; Julia Sein; Patrick Oellers; Carol L Karp Journal: Ophthalmology Date: 2014-01-09 Impact factor: 12.079
Authors: Andrew N Siedlecki; Stephanie Tapp; Anna N A Tosteson; Robin J Larson; Carol L Karp; Thomas Lietman; Michael E Zegans Journal: Cornea Date: 2016-05 Impact factor: 2.651
Authors: Benjamin J Thomas; Anat Galor; Afshan A Nanji; Fouad El Sayyad; Jianhua Wang; Sander R Dubovy; Madhura G Joag; Carol L Karp Journal: Ocul Surf Date: 2013-11-09 Impact factor: 5.033
Authors: Madhura G Joag; Adam Sise; Juan Carlos Murillo; Ibrahim Osama Sayed-Ahmed; James R Wong; Carolina Mercado; Anat Galor; Carol L Karp Journal: Ophthalmology Date: 2016-03-27 Impact factor: 12.079